Evaluation of the NORPACS risk score in STEMI patients undergoing primary PCI Beurteilung des NORPACS-Risikoscores bei Patienten mit STEMI und primärer Therapie mittels PCI


ERDOĞAN M., ÖZTÜRK S.

Herz, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1007/s00059-026-05399-1
  • Dergi Adı: Herz
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE, Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
  • Anahtar Kelimeler: Acute coronary syndrome, Coronary angioplasty, Prognosis, Risk stratification, ST-segment elevation myocardial infarction
  • Ankara Yıldırım Beyazıt Üniversitesi Adresli: Evet

Özet

Background: The no-reflow prediction in acute coronary syndrome (NORPACS) risk score was developed to predict the risk of no reflow after percutaneous coronary intervention (PCI). Objectives: This study sought to investigate whether the NORPACS risk score predicts the outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with primary PCI (pPCI). Methods: This retrospective study included 1725 patients. Receiver operating characteristic curve analysis revealed 6 as the optimal NORPACS risk score cut-off value. Patients were thus dichotomized into two groups: high (≥ 6) NORPACS risk score (n = 765) and low (< 6) NORPACS risk score (n = 960). Results: The frequency of in-hospital and all-cause mortality was significantly higher in the high NORPACS risk score group than in the low NORPACS risk score group. Compared with the baseline model, in the full model of binary logistic regression, the NORPACS risk score as both a continuous and a categorical variable emerged as an independent predictor of in-hospital mortality (odds ratio [OR]: 1.61, 95% confidence interval [CI]: 1.31–1.99, p < 0.001; OR: 4.96, 95% CI: 2.13–11.54, p < 0.001; respectively). Compared with the baseline model, in the full model of multivariable Cox proportional hazards regression analysis, the NORPACS risk score as both a continuous and a categorical variable emerged as an independent predictor of all-cause mortality (hazard ratio [HR]: 1.22, 95% CI: 1.07–1.38, p = 0.004; HR: 1.97, 95% CI: 1.27–3.06, p = 0.003; respectively). Conclusion: The NORPACS risk score can be used for prognostication of patients with STEMI treated with pPCI. It predicts in-hospital and long-term all-cause mortality and may serve as a practical tool for risk stratification in this patient population. Graphic abstract: (Figure presented.)